지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2018.1
- 수록면
- 230 - 238 (9page)
이용수
초록· 키워드
오류제보하기
Background: Tenofovir disoproxil fumarate (TDF) is relatively safe, although renal toxicity has been reported. In Nigeria, there is insufficient data on renal toxicity among patients on TDF. This study assesses TDF-associated tubular dysfunction among human immunodeficiency virus (HIV) patients at a hospital in Nigeria. Methods: In this cohort study, 104 adult HIV patients were recruited with a simple random technique from the outpatient clinic. Biochemical indices of renal function were estimated from serum and urine at the 16th and 24th week after an initial assessment at baseline. Results: There were no significant differences in baseline proteinuria or glycosuria between TDF and non-TDF groups. Mean baseline urine and serum parameters did not differ significantly between the two groups (P > 0.05). In the TDF group, all urine parameters differed significantly between baseline and 24th week values (P < 0.001). After 16 weeks, mean urine phosphate and urine uric acid increased significantly (P < 0.05) by 2.97 mg/dL and 50.9 mg/ dL, respectively, in the TDF group. The rise in mean urine glucose from baseline to the 24th week was more marked in the TDF than the non-TDF group (0.25 vs. 0.07 mmol/L). Higher mean differences in urine albumin were also recorded in the TDF group from baseline to the 24th week. Conclusion: Indicators of tubular dysfunction were markedly higher among patients on the TDF-based treatment regimen. Biomarkers of tubular dysfunction could be useful for detecting pre-symptomatic nephrotoxicity before marked reduction of glomerular filtration rate in HIV patients on TDF.
목차
등록된 정보가 없습니다.
참고문헌 (33)
참고문헌 신청
Weller IV / 2001 / ABC of AIDS: antiretroviral drugs / BMJ 322:1410~1412
Knobel H / 2008 / Risk of side effects associated with the use of nevirapine in treatment-naive patients, with respect to gender and CD4 cell count / HIV Med 9:14~18
Caron M / 2008 / Contribution of mitochondrial dysfunction and oxidative stress to cellular premature senescence induced by antiretroviral thymidine analogues / Antivir Ther 13:27~38
O'Brien ME / 2003 / Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort / J Acquir Immune Defic Syndr 34:407~414
Gallant JE / 2006 / Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV / N Engl J Med 354:251~260
Knobel H / 2008 / Risk of side effects associated with the use of nevirapine in treatment-naive patients, with respect to gender and CD4 cell count / HIV Med 9:14~18
Caron M / 2008 / Contribution of mitochondrial dysfunction and oxidative stress to cellular premature senescence induced by antiretroviral thymidine analogues / Antivir Ther 13:27~38
O'Brien ME / 2003 / Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort / J Acquir Immune Defic Syndr 34:407~414
Gallant JE / 2006 / Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV / N Engl J Med 354:251~260
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Tenofovir-associated nephrotoxicity in patients with chronic hepatitis B: Two cases
Clinical and Molecular Hepatology
2016 .01
-
The Incidence and Clinical Characteristics of Acute Serum Creatinine Elevation more than 1.5 mg/dL among the Patients Treated with Tenofovir/ Emtricitabine-containing HAART Regimens
Infection and Chemotherapy
2015 .01
-
Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir
Clinical and Molecular Hepatology
2017 .01
-
Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B
Clinical and Molecular Hepatology
2016 .01
-
Incidence and Risk Factors of Tenofovir Disoproxil Fumarate Induced Nephrotoxicity and Renal Function Recovery, a Hospital Case-Control Study
Infection and Chemotherapy
2023 .06
-
Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in Asian Subjects with Human Immunodeficiency Virus 1 Infection: A Sub- Analysis of Phase 3 Clinical Trials
Infection and Chemotherapy
2016 .01
-
Effects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virus-Related Compensated and Decompensated Cirrhosis
Gut and Liver
2017 .01
-
Treatment Outcome and Renal Safety of 3-Year Tenofovir Disoproxil Fumarate Therapy in Chronic Hepatitis B Patients with Preserved Glomerular Filtration Rate
Gut and Liver
2019 .01
-
A severe case of tenofovir-associated acute kidney injury requiring hemodialysis in a patient with chronic hepatitis B
Kidney Research and Clinical Practice
2020 .01
-
Management of Antiviral Resistance in Chronic Hepatitis B
Gut and Liver
2017 .01
-
Tenofovir and Entecavir Have Similar Renal Adverse Events on Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization
Journal of Liver Cancer
2019 .01
-
Long-term Nucleotide Analogue Treatment Has Higher Levels of Renal Toxicities than Does Entecavir in Patients with Chronic Hepatitis B
Gut and Liver
2020 .01
-
The efficacy of Tenofovir-based therapy in patients showing suboptimal response to Entecavir-Adefovr combination therapy
Clinical and Molecular Hepatology
2016 .01
-
Entecavir versus Tenofovir for the Prevention of Hepatocellular Carcinoma in Treatment-naïve Chronic Hepatitis B Patients in Korea
Journal of Korean Medical Science
2021 .01
-
Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide
Clinical and Molecular Hepatology
2024 .01
-
Change in Renal Function among HIV-Infected Koreans Receiving Tenofovir Disoproxil Fumarate-Backbone Antiretroviral Therapy: A 3-Year Follow-Up Study
Yonsei Medical Journal
2017 .07
-
Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study)
Clinical and Molecular Hepatology
2016 .01
-
Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)idenaïve patients
Clinical and Molecular Hepatology
2017 .01
-
The effect of nucleos(t)ide analogues on clinical outcomes of patients treated with transarterial chemoembolization and radiofrequency ablation for hepatitis B virus-related hepatocellular carcinoma
Journal of Liver Cancer
2021 .09
-
Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma
Clinical and Molecular Hepatology
2021 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0